Wanbury Limited Reports Q2 FY27 Results With 14% Revenue Growth
Wanbury Ltd · Investor Presentation · 18 Nov 2026, 6:10 pm
Wanbury Limited Reports Q2 FY27 Results With 14% Revenue Growth Wanbury reported Q2 FY27 revenue from operations of ₹182.91 cr, up 14% YoY and 10% QoQ, driven by a 16% YoY rise in API revenue to ₹161 cr. Gross margin declined 405 bps YoY to 54.18%, though recovering 167 bps QoQ as raw material price increases are being passed through. EBITDA reached ₹26.21 cr, up 1% YoY and 58% QoQ, with margins at 14.33%. PAT fell 22% YoY but surged 266% QoQ to ₹11.88 cr. H1 FY27 revenue grew 8% YoY to ₹348.49 cr.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement · 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates · 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. · 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. · 06 Nov 2026
- Financial Results as on 30th September, 2026 · 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 · 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. · 30 Oct 2026
